DataTap integrates relevant patient information into the problem list for rapid processing and decision-making by the clinician. This reduces burnout while enhancing safety and efficiency.
BLA service closes current care gap by using technology and care collaboration to provide the right care, at the right time, to every mom and child preventing Maternal -Child morbidity and mortality.
MedAux automates outpatient follow-ups from preparation to post-discharge.
Iris OB Health applies a patent-pending, risk stratification algorithm to clinical data in order to identify and offer appropriate treatment to women at risk of developing postpartum depression.
E-Triage supports emergency department triage decision-making to improve risk-stratification and decrease patient waiting
McRISC© offers the first and only acute and chronic illness-driven substance use assessment, prevention and treatment guidance for healthcare and other providers.
We provide Interaction Recommendations specific to each patient that is being taken care of, improving the patient experience.
Mining the gut microbiome for biomarkers and novel therapeutic molecules
Promoting a B2B E-commerce platform for the healthcare industry
A revolutionary product capable of stopping the progression of aging and related diseases in patients.
This program will help to educate people of the growing need for live donors, the process it takes to become a live donor, help those interested in becoming donors to get in touch with the right facil
A robot that only needs a small perforation to do the surgery, so the patient will be healed faster and spend less time in the hospital.
Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.